Fatty acid transport protein 2 reprograms neutrophils in cancer

Filippo Veglia, Vladimir A. Tyurin, Maria Blasi, Alessandra De Leo, Andrew V. Kossenkov, Laxminarasimha Donthireddy, Tsun Ki Jerrick To, Zach Schug, Subhasree Basu, Fang Wang, Emanuela Ricciotti, Concetta DiRusso, Maureen E. Murphy, Robert H. Vonderheide, Paul M. Lieberman, Charles Mulligan, Brian Nam, Neil Hockstein, Gregory Masters, Michael GuarinoCindy Lin, Yulia Nefedova, Paul Black, Valerian E. Kagan, Dmitry I. Gabrilovich

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that are crucial for the regulation of immune responses in cancer. These cells contribute to the failure of cancer therapies and are associated with poor clinical outcomes. Despite recent advances in the understanding of PMN-MDSC biology, the mechanisms responsible for the pathological activation of neutrophils are not well defined, and this limits the selective targeting of these cells. Here we report that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2). Overexpression of FATP2 in PMN-MDSCs was controlled by granulocyte–macrophage colony-stimulating factor, through the activation of the STAT5 transcription factor. Deletion of FATP2 abrogated the suppressive activity of PMN-MDSCs. The main mechanism of FATP2-mediated suppressive activity involved the uptake of arachidonic acid and the synthesis of prostaglandin E 2 . The selective pharmacological inhibition of FATP2 abrogated the activity of PMN-MDSCs and substantially delayed tumour progression. In combination with checkpoint inhibitors, FATP2 inhibition blocked tumour progression in mice. Thus, FATP2 mediates the acquisition of immunosuppressive activity by PMN-MDSCs and represents a target to inhibit the functions of PMN-MDSCs selectively and to improve the efficiency of cancer therapy.

Original languageEnglish (US)
Pages (from-to)73-78
Number of pages6
JournalNature
Volume569
Issue number7754
DOIs
StatePublished - May 2 2019

Fingerprint

Fatty Acid Transport Proteins
Neutrophils
Fatty Acids
Neoplasms
STAT5 Transcription Factor
Colony-Stimulating Factors
Neutrophil Activation
Second Primary Neoplasms
Myeloid-Derived Suppressor Cells
Immunosuppressive Agents
Prostaglandins E
Arachidonic Acid
Cell Biology
Up-Regulation
Pharmacology

ASJC Scopus subject areas

  • General

Cite this

Veglia, F., Tyurin, V. A., Blasi, M., De Leo, A., Kossenkov, A. V., Donthireddy, L., ... Gabrilovich, D. I. (2019). Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature, 569(7754), 73-78. https://doi.org/10.1038/s41586-019-1118-2

Fatty acid transport protein 2 reprograms neutrophils in cancer. / Veglia, Filippo; Tyurin, Vladimir A.; Blasi, Maria; De Leo, Alessandra; Kossenkov, Andrew V.; Donthireddy, Laxminarasimha; To, Tsun Ki Jerrick; Schug, Zach; Basu, Subhasree; Wang, Fang; Ricciotti, Emanuela; DiRusso, Concetta; Murphy, Maureen E.; Vonderheide, Robert H.; Lieberman, Paul M.; Mulligan, Charles; Nam, Brian; Hockstein, Neil; Masters, Gregory; Guarino, Michael; Lin, Cindy; Nefedova, Yulia; Black, Paul; Kagan, Valerian E.; Gabrilovich, Dmitry I.

In: Nature, Vol. 569, No. 7754, 02.05.2019, p. 73-78.

Research output: Contribution to journalArticle

Veglia, F, Tyurin, VA, Blasi, M, De Leo, A, Kossenkov, AV, Donthireddy, L, To, TKJ, Schug, Z, Basu, S, Wang, F, Ricciotti, E, DiRusso, C, Murphy, ME, Vonderheide, RH, Lieberman, PM, Mulligan, C, Nam, B, Hockstein, N, Masters, G, Guarino, M, Lin, C, Nefedova, Y, Black, P, Kagan, VE & Gabrilovich, DI 2019, 'Fatty acid transport protein 2 reprograms neutrophils in cancer', Nature, vol. 569, no. 7754, pp. 73-78. https://doi.org/10.1038/s41586-019-1118-2
Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019 May 2;569(7754):73-78. https://doi.org/10.1038/s41586-019-1118-2
Veglia, Filippo ; Tyurin, Vladimir A. ; Blasi, Maria ; De Leo, Alessandra ; Kossenkov, Andrew V. ; Donthireddy, Laxminarasimha ; To, Tsun Ki Jerrick ; Schug, Zach ; Basu, Subhasree ; Wang, Fang ; Ricciotti, Emanuela ; DiRusso, Concetta ; Murphy, Maureen E. ; Vonderheide, Robert H. ; Lieberman, Paul M. ; Mulligan, Charles ; Nam, Brian ; Hockstein, Neil ; Masters, Gregory ; Guarino, Michael ; Lin, Cindy ; Nefedova, Yulia ; Black, Paul ; Kagan, Valerian E. ; Gabrilovich, Dmitry I. / Fatty acid transport protein 2 reprograms neutrophils in cancer. In: Nature. 2019 ; Vol. 569, No. 7754. pp. 73-78.
@article{bd075892428944c8bf057aa580850e78,
title = "Fatty acid transport protein 2 reprograms neutrophils in cancer",
abstract = "Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that are crucial for the regulation of immune responses in cancer. These cells contribute to the failure of cancer therapies and are associated with poor clinical outcomes. Despite recent advances in the understanding of PMN-MDSC biology, the mechanisms responsible for the pathological activation of neutrophils are not well defined, and this limits the selective targeting of these cells. Here we report that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2). Overexpression of FATP2 in PMN-MDSCs was controlled by granulocyte–macrophage colony-stimulating factor, through the activation of the STAT5 transcription factor. Deletion of FATP2 abrogated the suppressive activity of PMN-MDSCs. The main mechanism of FATP2-mediated suppressive activity involved the uptake of arachidonic acid and the synthesis of prostaglandin E 2 . The selective pharmacological inhibition of FATP2 abrogated the activity of PMN-MDSCs and substantially delayed tumour progression. In combination with checkpoint inhibitors, FATP2 inhibition blocked tumour progression in mice. Thus, FATP2 mediates the acquisition of immunosuppressive activity by PMN-MDSCs and represents a target to inhibit the functions of PMN-MDSCs selectively and to improve the efficiency of cancer therapy.",
author = "Filippo Veglia and Tyurin, {Vladimir A.} and Maria Blasi and {De Leo}, Alessandra and Kossenkov, {Andrew V.} and Laxminarasimha Donthireddy and To, {Tsun Ki Jerrick} and Zach Schug and Subhasree Basu and Fang Wang and Emanuela Ricciotti and Concetta DiRusso and Murphy, {Maureen E.} and Vonderheide, {Robert H.} and Lieberman, {Paul M.} and Charles Mulligan and Brian Nam and Neil Hockstein and Gregory Masters and Michael Guarino and Cindy Lin and Yulia Nefedova and Paul Black and Kagan, {Valerian E.} and Gabrilovich, {Dmitry I.}",
year = "2019",
month = "5",
day = "2",
doi = "10.1038/s41586-019-1118-2",
language = "English (US)",
volume = "569",
pages = "73--78",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7754",

}

TY - JOUR

T1 - Fatty acid transport protein 2 reprograms neutrophils in cancer

AU - Veglia, Filippo

AU - Tyurin, Vladimir A.

AU - Blasi, Maria

AU - De Leo, Alessandra

AU - Kossenkov, Andrew V.

AU - Donthireddy, Laxminarasimha

AU - To, Tsun Ki Jerrick

AU - Schug, Zach

AU - Basu, Subhasree

AU - Wang, Fang

AU - Ricciotti, Emanuela

AU - DiRusso, Concetta

AU - Murphy, Maureen E.

AU - Vonderheide, Robert H.

AU - Lieberman, Paul M.

AU - Mulligan, Charles

AU - Nam, Brian

AU - Hockstein, Neil

AU - Masters, Gregory

AU - Guarino, Michael

AU - Lin, Cindy

AU - Nefedova, Yulia

AU - Black, Paul

AU - Kagan, Valerian E.

AU - Gabrilovich, Dmitry I.

PY - 2019/5/2

Y1 - 2019/5/2

N2 - Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that are crucial for the regulation of immune responses in cancer. These cells contribute to the failure of cancer therapies and are associated with poor clinical outcomes. Despite recent advances in the understanding of PMN-MDSC biology, the mechanisms responsible for the pathological activation of neutrophils are not well defined, and this limits the selective targeting of these cells. Here we report that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2). Overexpression of FATP2 in PMN-MDSCs was controlled by granulocyte–macrophage colony-stimulating factor, through the activation of the STAT5 transcription factor. Deletion of FATP2 abrogated the suppressive activity of PMN-MDSCs. The main mechanism of FATP2-mediated suppressive activity involved the uptake of arachidonic acid and the synthesis of prostaglandin E 2 . The selective pharmacological inhibition of FATP2 abrogated the activity of PMN-MDSCs and substantially delayed tumour progression. In combination with checkpoint inhibitors, FATP2 inhibition blocked tumour progression in mice. Thus, FATP2 mediates the acquisition of immunosuppressive activity by PMN-MDSCs and represents a target to inhibit the functions of PMN-MDSCs selectively and to improve the efficiency of cancer therapy.

AB - Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that are crucial for the regulation of immune responses in cancer. These cells contribute to the failure of cancer therapies and are associated with poor clinical outcomes. Despite recent advances in the understanding of PMN-MDSC biology, the mechanisms responsible for the pathological activation of neutrophils are not well defined, and this limits the selective targeting of these cells. Here we report that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2). Overexpression of FATP2 in PMN-MDSCs was controlled by granulocyte–macrophage colony-stimulating factor, through the activation of the STAT5 transcription factor. Deletion of FATP2 abrogated the suppressive activity of PMN-MDSCs. The main mechanism of FATP2-mediated suppressive activity involved the uptake of arachidonic acid and the synthesis of prostaglandin E 2 . The selective pharmacological inhibition of FATP2 abrogated the activity of PMN-MDSCs and substantially delayed tumour progression. In combination with checkpoint inhibitors, FATP2 inhibition blocked tumour progression in mice. Thus, FATP2 mediates the acquisition of immunosuppressive activity by PMN-MDSCs and represents a target to inhibit the functions of PMN-MDSCs selectively and to improve the efficiency of cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85064540512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064540512&partnerID=8YFLogxK

U2 - 10.1038/s41586-019-1118-2

DO - 10.1038/s41586-019-1118-2

M3 - Article

C2 - 30996346

AN - SCOPUS:85064540512

VL - 569

SP - 73

EP - 78

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7754

ER -